Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review

Gerontology

Volumn 60, Issue 5, 2014, Pages 381-385

  Boutajangout, Allal ^a,b   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Active immunization; Aggregation; Alzheimer's disease; Glycogen synthase kinase 3; Immunotherapy; Passive immunization; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; MAPT PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CLINICAL FEATURE; DEMENTIA; HUMAN; NEUROFIBRILLARY TANGLE; NEUROPIL THREAD; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; VASCULAR AMYLOIDOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; TAU PROTEINS;

EID: 84927662307     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000358875     Document Type: Short Survey

References (32)

1. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns N, Davies P, Tredici KD, Duyckaerts C, Frosch MP, Hof PR, Hulette C, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee A, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG: Correlation of Alzheimer's disease neuropathologic changes with cognitive status: a review of the literature. J Neuropath Exp Neurol 2012;71:362-381.
2. Ashe KH, Aguzzi A: Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 2013;7:55-59.
3. Gaugler J, James B, Johnson T, Scholz K, Weuve J: Alzheimer's Disease Facts and Figures 2013. Alzheimer's Disease Association, 2013.
4. Wisniewski T, Goni F: Immunotherapy for Alzheimer's disease. Biochem Pharmacol 2014;88:499-507.
5. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
6. Bettens K, Sleegers K, Van BC: Genetic insights in Alzheimer's disease. Lancet Neurol 2013;12:92-104.
7. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S: Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurol 2005;64:94-101.
8. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA: Long-term effects of Aβ42 immunization in Alzheimer's disease: immune response, plaque removal and clinical function. Lancet 2008;372:216-223.
9. Farlow MR, Brosch JR: Immunotherapy for Alzheimer's disease. Neurol Clin 2013;31:869-878.
10. Yoshiyama Y, Lee VM, Trojanowski JQ: Therapeutic strategies for tau-mediated neurodegeneration. J Neurol Neurosurg Psychiatry 2013;84:784-795.
11. Tell V, Hilgeroth A: Recent developments of protein kinase inhibitors as potential AD therapeutics. Front Cell Neurosci 2013;7:189.
12. Anand R, Gill KD, Mahdi AA: Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 2014;76(Pt A):27-50.
13. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F: Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but preformed neurofibrillary tangles do not revert. J Neurochem 2006;99:1445-1455.
14. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, Frolich L, Schroder J, Schonknecht P, Riepe MW, Kraft I, Gasser T, Leyhe T, Moller HJ, Kurz A, Basun H: Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009;70:922-931.
15. Tariot PN, Aisen PS: Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry 2009;70:919-921.
16. Del ST, Steinwachs KC, Gertz HJ, Andres MV, Gomez-Carrillo B, Medina M, Vericat JA, Redondo P, Fleet D, Leon T: Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis 2013;33:205-215.
17. Bulic B, Pickhardt M, Mandelkow E: Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem 2013;56:4135-4155.
18. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996;93:11213-11218.
19. Giommarelli C, Zuco V, Favini E, Pisano C, Dal PF, De TN, Zunino F: The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci 2010;67:995-1004.
20. Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA: Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem 2013;288:4056-4065.
21. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007;27:9115-9129.
22. Boutajangout A, Frangione B, Wisniewski T, Brion JP, Sigurdsson EM: Influence of presenilin mutation on tau pathology in novel Alzheimer's disease mouse model. Alzheimers Dement 2009;5:P445-P446.
23. Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010;30:16559-16566.
24. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H: Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010;224:472-485.
25. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L: Targeting phospho-Ser422 by active tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012;9:397-405.
26. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM: Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011;118:658-667.
27. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M: Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011;286:34457-34467.
28. d'Abramo C, Acker CM, Jimenez HT, Davies P: Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 2013;8:e62402.
29. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM: Anti-tau antibodies that block tau aggregate seeding In vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013;80:402-414.
30. Goni F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, Mehta PD, Wisniewski T: Immunomodulation targeting both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. J Neuroinflammation 2013;10:150.
31. Congdon EE, Gu J, Sait HB, Sigurdsson EM: Antibody uptake into neurons occurs primarily via clathrin-dependent fcγ receptor endocytosis, and is a prerequisite for acute tau clearance. J Biol Chem 2013;288:35452-35465.
32. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M: Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009;11:909-913.